<p>Zentalis Pharmaceuticals, Inc.（纳斯达克代码：ZNTL - 获取免费报告）在覆盖该公司的九家券商中获得了 “持有” 的共识评级，Marketbeat.com 报道。五位股票研究分析师对该股票给予了持有推荐，四位则给予了买入推荐。在过去一年中，覆盖该股票的券商的平均 12 个月目标价为 8.24 美元。</p>
<p>一些股票分析师最近对 ZNTL 股票发表了评论。Wedbush 在 5 月 15 日的报告中重申了 “中性” 评级，并对 Zentalis Pharmaceuticals 的股票设定了 4.00 美元的目标价。HC Wainwright 在 5 月 15 日的报告中重申了 “买入” 评级，并设定了 10.00 美元的目标价。</p>
<p><strong>查看我们最新的 ZNTL 股票分析</strong></p>
<h2>Zentalis Pharmaceuticals 价格表现</h2>
<p>Zentalis Pharmaceuticals 的股票在周二开盘价为 1.51 美元。该股票的 50 日移动平均线为 1.33 美元，200 日移动平均线为 2.00 美元。该公司的市值为 1.0865 亿美元，市盈率为-0.61，贝塔值为 1.61。Zentalis Pharmaceuticals 的 12 个月低点为 1.01 美元，12 个月高点为 8.87 美元。</p>
<p>Zentalis Pharmaceuticals（纳斯达克代码：ZNTL - 获取免费报告）最近于 5 月 14 日发布了季度财报。该公司报告季度每股收益（EPS）为-0.67 美元，符合分析师的共识预期（-0.67 美元）。研究分析师预计 Zentalis Pharmaceuticals 在当前年度将发布-2.42 美元的每股收益。</p>
<h2>内部人士下注</h2>
<p>在其他 Zentalis Pharmaceuticals 的新闻中，董事 Scott Dunseth Myers 在 4 月 30 日的交易中购买了 21,000 股该公司的股票。这些股票的平均购买成本为每股 1.40 美元，总交易额为 29,400.00 美元。收购后，该董事现在直接拥有 281,192 股该公司的股票，价值 393,668.80 美元。这笔交易代表了他们持股比例的 8.07% 的增加。该交易已在证券交易委员会的备案中披露，您可以通过此链接访问。公司内部人士持有 1.90% 的股票。</p>
<h2>机构投资者对 Zentalis Pharmaceuticals 的看法</h2>
<p>几家对冲基金和其他机构投资者最近买卖了 ZNTL 的股票。Savant Capital LLC 在第四季度购买了 Zentalis Pharmaceuticals 的新股份，价值约 72,000 美元。Ieq Capital LLC 在第四季度获得了 Zentalis Pharmaceuticals 的新头寸，价值约 46,000 美元。Anfield Capital Management LLC 在第四季度将其在 Zentalis Pharmaceuticals 的持股增加了 100.0%。Anfield Capital Management LLC 现在拥有 129,318 股该公司的股票，价值 392,000 美元，此前在上个季度又收购了 64,659 股。Charles Schwab Investment Management Inc.在第四季度将其在 Zentalis Pharmaceuticals 的持股增加了 22.4%。Charles Schwab Investment Management Inc.现在拥有 497,362 股该公司的股票，价值 1,507,000 美元，此前在上个季度又收购了 91,152 股。最后，Raymond James Financial Inc.在第四季度获得了 Zentalis Pharmaceuticals 的新头寸，价值约 68,000 美元。</p>
<h2>关于 Zentalis Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Zentalis Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于发现和开发小分子治疗药物，用于治疗各种癌症。其产品候选药物包括 ZN-c3，一种 WEE1 抑制剂，针对晚期实体肿瘤和血液恶性肿瘤的治疗；作为单药治疗子宫浆液性癌症的二期临床试验；在 Cyclin E1 驱动的高等级浆液性卵巢癌、输卵管癌或原发性腹膜癌的二期临床试验；与 PARPi 联合用于铂耐药卵巢癌的 1/2 期临床试验；与化疗联合用于铂耐药卵巢癌、腹膜癌或输卵管癌的 1b 期临床试验；与化疗联合用于复发或难治性骨肉瘤的 1/2 期临床试验；与 encorafenib 和 cetuximab 联合用于突变转移性结直肠癌的 1/2 期临床试验；以及与化疗联合用于胰腺癌的 1/2 期临床试验。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Zentalis Pharmaceuticals</li>
<li>卖空 - 利弊分析</li>
<li>新催化剂将推动 NVIDIA 的股价更高</li>
<li>如何利用高贝塔股票最大化投资收益</li>
<li>中国市场动向：MCHI、PDD、BIDU 显示看涨趋势</li>
<li>什么是成长股及其投资方式</li>
<li>Palantir 抵御空头，领跑 2025 年标准普尔 500 指数</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Zentalis Pharmaceuticals 吗？</h2>
<p>在考虑 Zentalis Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意之前立即购买……而 Zentalis Pharmaceuticals 并不在名单上。</p>
<p>虽然 Zentalis Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ZNTL

<p>Zentalis Pharmaceuticals, Inc.（纳斯达克代码：ZNTL）获得了九家券商的共识评级为 “持有”，其中五位分析师建议持有，四位建议买入。12 个月的平均目标价格为 8.24 美元。该股票开盘价为 1.51 美元，12 个月的最低价为 1.01 美元，最高价为 8.87 美元。最近，董事 Scott Dunseth Myers 以每股 1.40 美元购买了 21,000 股。机构投资者也表现活跃，多家机构在该公司增持了新股份</p>

<p>Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been given a consensus rating of &#34;Hold&#34; by the nine brokerages that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $8.24.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals, Inc.（纳斯达克代码：ZNTL - 获取免费报告）在覆盖该公司的九家券商中获得了 “持有” 的共识评级，Marketbeat.com 报道。五位股票研究分析师对该股票给予了持有推荐，四位则给予了买入推荐。在过去一年中，覆盖该股票的券商的平均 12 个月目标价为 8.24 美元。</p>
</div><p>A number of equities analysts have recently commented on ZNTL shares. Wedbush restated a &#34;neutral&#34; rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. HC Wainwright reiterated a &#34;buy&#34; rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th.</p>
<div class="lb-trans"><p>一些股票分析师最近对 ZNTL 股票发表了评论。Wedbush 在 5 月 15 日的报告中重申了 “中性” 评级，并对 Zentalis Pharmaceuticals 的股票设定了 4.00 美元的目标价。HC Wainwright 在 5 月 15 日的报告中重申了 “买入” 评级，并设定了 10.00 美元的目标价。</p>
</div><p><strong>View Our Latest Stock Analysis on ZNTL</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 ZNTL 股票分析</strong></p>
</div><h2>Zentalis Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Zentalis Pharmaceuticals 价格表现</h2>
</div><p>Zentalis Pharmaceuticals stock opened at $1.51 on Tuesday. The stock's 50-day moving average is $1.33 and its 200-day moving average is $2.00. The company has a market cap of $108.65 million, a price-to-earnings ratio of -0.61 and a beta of 1.61. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $8.87.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals 的股票在周二开盘价为 1.51 美元。该股票的 50 日移动平均线为 1.33 美元，200 日移动平均线为 2.00 美元。该公司的市值为 1.0865 亿美元，市盈率为-0.61，贝塔值为 1.61。Zentalis Pharmaceuticals 的 12 个月低点为 1.01 美元，12 个月高点为 8.87 美元。</p>
</div><p>Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, hitting analysts' consensus estimates of ($0.67). Research analysts anticipate that Zentalis Pharmaceuticals will post -2.42 EPS for the current year.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals（纳斯达克代码：ZNTL - 获取免费报告）最近于 5 月 14 日发布了季度财报。该公司报告季度每股收益（EPS）为-0.67 美元，符合分析师的共识预期（-0.67 美元）。研究分析师预计 Zentalis Pharmaceuticals 在当前年度将发布-2.42 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers acquired 21,000 shares of the company's stock in a transaction on Wednesday, April 30th. The shares were bought at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the acquisition, the director now directly owns 281,192 shares of the company's stock, valued at $393,668.80. This trade represents a 8.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. 1.90% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Zentalis Pharmaceuticals 的新闻中，董事 Scott Dunseth Myers 在 4 月 30 日的交易中购买了 21,000 股该公司的股票。这些股票的平均购买成本为每股 1.40 美元，总交易额为 29,400.00 美元。收购后，该董事现在直接拥有 281,192 股该公司的股票，价值 393,668.80 美元。这笔交易代表了他们持股比例的 8.07% 的增加。该交易已在证券交易委员会的备案中披露，您可以通过此链接访问。公司内部人士持有 1.90% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Zentalis Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Zentalis Pharmaceuticals 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of ZNTL. Savant Capital LLC purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter worth approximately $72,000. Ieq Capital LLC acquired a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth approximately $46,000. Anfield Capital Management LLC grew its position in shares of Zentalis Pharmaceuticals by 100.0% in the 4th quarter. Anfield Capital Management LLC now owns 129,318 shares of the company's stock worth $392,000 after acquiring an additional 64,659 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Zentalis Pharmaceuticals by 22.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company's stock worth $1,507,000 after acquiring an additional 91,152 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth approximately $68,000.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近买卖了 ZNTL 的股票。Savant Capital LLC 在第四季度购买了 Zentalis Pharmaceuticals 的新股份，价值约 72,000 美元。Ieq Capital LLC 在第四季度获得了 Zentalis Pharmaceuticals 的新头寸，价值约 46,000 美元。Anfield Capital Management LLC 在第四季度将其在 Zentalis Pharmaceuticals 的持股增加了 100.0%。Anfield Capital Management LLC 现在拥有 129,318 股该公司的股票，价值 392,000 美元，此前在上个季度又收购了 64,659 股。Charles Schwab Investment Management Inc.在第四季度将其在 Zentalis Pharmaceuticals 的持股增加了 22.4%。Charles Schwab Investment Management Inc.现在拥有 497,362 股该公司的股票，价值 1,507,000 美元，此前在上个季度又收购了 91,152 股。最后，Raymond James Financial Inc.在第四季度获得了 Zentalis Pharmaceuticals 的新头寸，价值约 68,000 美元。</p>
</div><h2>About Zentalis Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Zentalis Pharmaceuticals</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于发现和开发小分子治疗药物，用于治疗各种癌症。其产品候选药物包括 ZN-c3，一种 WEE1 抑制剂，针对晚期实体肿瘤和血液恶性肿瘤的治疗；作为单药治疗子宫浆液性癌症的二期临床试验；在 Cyclin E1 驱动的高等级浆液性卵巢癌、输卵管癌或原发性腹膜癌的二期临床试验；与 PARPi 联合用于铂耐药卵巢癌的 1/2 期临床试验；与化疗联合用于铂耐药卵巢癌、腹膜癌或输卵管癌的 1b 期临床试验；与化疗联合用于复发或难治性骨肉瘤的 1/2 期临床试验；与 encorafenib 和 cetuximab 联合用于突变转移性结直肠癌的 1/2 期临床试验；以及与化疗联合用于胰腺癌的 1/2 期临床试验。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Zentalis Pharmaceuticals</li>
<li>Short Selling - The Pros and Cons</li>
<li>New Catalysts to Drive NVIDIA’s Stock Price Even Higher</li>
<li>How to Use High Beta Stocks to Maximize Your Investing Profits</li>
<li>China Market Movers: MCHI, PDD, BIDU Show Bullish Trends</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>Palantir Defies Bears, Leads S&amp;P 500 in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Zentalis Pharmaceuticals</li>
<li>卖空 - 利弊分析</li>
<li>新催化剂将推动 NVIDIA 的股价更高</li>
<li>如何利用高贝塔股票最大化投资收益</li>
<li>中国市场动向：MCHI、PDD、BIDU 显示看涨趋势</li>
<li>什么是成长股及其投资方式</li>
<li>Palantir 抵御空头，领跑 2025 年标准普尔 500 指数</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ZNTL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Zentalis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Zentalis Pharmaceuticals 吗？</h2>
</div><p>Before you consider Zentalis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Zentalis Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意之前立即购买……而 Zentalis Pharmaceuticals 并不在名单上。</p>
</div><p>While Zentalis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Zentalis Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

ZeZentalis Pharma（纳斯达克股票代码：ZNTL）被券商给予平均评级为 “持有”